$AGX

Getsinger Peter W sold $4.7M of AGX

Getsinger Peter W sold 6,728 shares of ARGAN INC (AGX) at an average of $705.78 ($699.00–$708.65, $4.75M total) across 2 trades over 2026-06-16 to 2026-06-17.

Original reporting
SEC EDGAR · Getsinger Peter W
Published Jun 17, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AGX
Neutral
medium confidence
Mentioned
$AGX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AGXNeutralLow
01

Why it matters

The newest fact is the director’s open-market sale of 6,728 shares (about $4.75M) with trades on 6/16–6/17 and holdings after sale of 4,880 shares; no 10b5-1 plan is indicated.

02

Market read

Traders may monitor AGX for sentiment/flow effects from insider selling, but the filing alone doesn’t provide a fundamental catalyst.

03

What to watch

Insider sales often have weak predictive power without accompanying changes in guidance, contracts, or ownership concentration; also, the article doesn’t state whether other insiders/large holders acted similarly.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-17; insider sale disclosed for trades dated 2026-06-16 to 2026-06-17.

Background

The article is an SEC Form 4 insider transaction disclosure for Argan Inc (AGX) by director Peter W Getsinger.

Company-level read

Ticker impact

$AGXNeutralMedium confidence
Context

Argan Inc director Peter W Getsinger sold 6,728 shares in open-market transactions for about $4.75M, per a new SEC Form 4.

Expected impact

Modest near-term negative/neutral bias; no clear directional catalyst beyond insider-sale optics.

Evidence & confidence

The filing is a primary-source Form 4 showing size ($4.75M) and timing (6/16–6/17) but provides no stated reason, and it explicitly notes no 10b5-1 plan.

Market effects

Minimal—this is company-specific insider activity with no sector-wide regulatory or earnings signal.

None indicated; disclosure is US-focused and not tied to broader regional macro events.

Low—no international deal, guidance, or regulatory action is described.

Counterpoint

The sale may be for diversification, taxes, or pre-planned liquidity needs; absence of a 10b5-1 plan doesn’t automatically imply negative fundamentals.

Key entities

  • Argan Inc

    Subject of the Form 4 insider sale disclosure; director Peter W Getsinger sold shares totaling ~$4.75M.

  • Peter W Getsinger

    Director who executed the open-market sales; holdings after transaction reported as 4,880 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AGXMedAI 8/10

Argan’s (AGX) Power Boom Comes With A Margin Catch

Argan (AGX) reported record Q2 revenue of $384.0M (+61.5% YoY) and net income of $53.3M, driven by its Power segment. Gross margin slipped to 19.3%, and backlog decreased to $2.5B. The company is debt-free with $1.03B in cash, returning $51.7M to shareholders. Management expects new projects but faces regulatory challenges and margin compression.

$AGXHigh

Why Argan Stock Swooned by Almost 8% Today

Argan (AGX) stock fell 8% after Piper Sandler analyst Dimple Gosai initiated coverage with an underweight rating and a $273 price target, citing capacity limits and a potential peak in project awards.

$AGXMed

Argan (AGX) Q2 2027 Earnings Call Transcript

Argan (AGX) reported Q2 2027 revenue of $384.0M, up 61.5%, with net income of $53.3M ($3.76 per diluted share). Power segment revenue grew 53% YoY to $301M, while Industrial segment revenue rose 111% to $76M. Consolidated backlog decreased to $2.5B. The company plans to complete a new fabrication facility in North Carolina by Q3 2027.

$AGXMedAI 8/10

Is Argan Worth Buying as Growth Surges but Valuation Stays Elevated?

Argan, Inc. (AGX) reported 56.5% revenue growth to $674.9M and adjusted EBITDA growth to $126.5M in H1 2027. The company expects 45.4% sales and 38% earnings growth for fiscal 2027, with a $2.5B backlog. However, margins have declined, and valuation remains high. Management highlights multi-year visibility but warns of execution risks.